Search Result

Results for "

anti-diabetes

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amylases (2) Calcium Channel (3) COX (2) Endogenous Metabolite (2) FXR (1) Glycosidase (7) HMG-CoA Reductase (HMGCR) (1) Insulin Receptor (1) PPAR (1) TRP Channel (3)
By Research Areas:	Cancer (6) Cardiovascular Disease (3) Endocrinology (1) Inflammation/Immunology (3) Metabolic Disease (14) Neurological Disease (5)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-138937

NDB	FXR	Metabolic Disease
NDB is a selective human FXRα (hFXRα) antagonist that is effective in modulating transcription of FXRα downstream genes. NDB can be used in anti-diabetes research .

HY-N0064

Macelignan 3 Publications Verification (+)-Anwulignan; Anwuligan	COX	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Macelignan ((+)-Anwulignan; Anwuligan)?is an orally active lignan isolated from Myristica fragrans. Macelignan possesses many pharmacological activities, including anti-inflammatory, anti-cancer, anti-diabetes, and neuroprotective activities .

HY-116330A

Hyperforin dicyclohexylammonium salt 1 Publications Verification Hyperforin DCHA	TRP Channel Calcium Channel	Neurological Disease Cancer
Hyperforin dicyclohexylammonium salt (Hyperforin DCHA) is a transient receptor canonical 6 (TRPC6) channels activator. Hyperforin dicyclohexylammonium salt modulates Ca ²⁺ levels by activating Ca ²⁺-conducting non-selective canonical TRPC6 channels. Hyperforin dicyclohexylammonium salt also shows diverse pharmacological activities including anti-depression, anti-tumor, anti-dementia, anti-diabetes. Hyperforin dicyclohexylammonium salt modulates γδ T cells to secret IL-17α, improves Imiquimod (HY-B0180)-induced psoriasis-like mice model .

HY-N8947

Glyurallin A	Endogenous Metabolite Glycosidase	Metabolic Disease
Glyurallin A (Compound 79) is isolated from the naturalGlycyrrhiza uralensis. Glyurallin A inhibitsα-Glucosidase(HY-P2802)(IC₅₀=0.3 μM). Glyurallin A can be used in the study of anti-diabetes .

HY-N0064R

Macelignan (Standard)	COX	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Macelignan (Standard) is the analytical standard of Macelignan. This product is intended for research and analytical applications. Macelignan ((+)-Anwulignan; Anwuligan) is an orally active lignan isolated from Myristica fragrans. Macelignan possesses many pharmacological activities, including anti-inflammatory, anti-cancer, anti-diabetes, and neuroprotective activities .

HY-N2924

β-Amyrin palmitate	HMG-CoA Reductase (HMGCR)	Cardiovascular Disease Endocrinology
β-Amyrin palmitate shows HMG-CoA reductase inhibition . And β-Amyrin palmitate has anti-diabetes mellitus activity .

HY-163433

α-Glucosidase-IN-57	Glycosidase	Metabolic Disease
α-Glucosidase-IN-57 (Compound 10c) is a competitive and orally active α-glucosidase inhibitor with an IC₅₀ value of 0.180 μM and a K_i of 0.15 μM. α-Glucosidase-IN-57 can reduce fasting and overall blood glucose levels in mice, and can be used for anti-diabetes research .

HY-N12161

3-Acetyl-11-keto-ursolic acid	Others	Metabolic Disease
3-Acetyl-11-keto-ursolic acid (Compound 18) is a triterpenoid compound derived from Eriobotrya japonicaleaves. 3-Acetyl-11-keto-ursolic acid has 11B-hydroxysteroid dehydrogenase 1 (11b-HSD1) inhibitory activity. 3-Acetyl-11-keto-ursolic acid can be used for anti-diabetes research .

HY-171836

c9,t11-CLA	Endogenous Metabolite	Cardiovascular Disease Metabolic Disease Cancer
c9,t11-CLA is an active isomer of conjugated linoleic acid (CLA). c9,t11-CLA has multiple physiological activities such as anti-cancer, anti-atherosclerosis, anti-obesity, anti-diabetes and anti-hypertension. The main regulatory mechanism of c9,t11-CLA is related to the regulation of cell signaling pathways and metabolic processes. c9,t11-CLA can be used in functional foods, drug development and health-related research .

HY-116330

Hyperforin	Calcium Channel TRP Channel	Neurological Disease Inflammation/Immunology
Hyperforin is a transient receptor canonical 6 (TRPC6) channels activator. Hyperforin modulates Ca ²⁺ levels by activating Ca ²⁺-conducting non-selective canonical TRPC6 channels and triggers adipose tissue thermogenesis via the Dlat-AMPK signaling axis to suppress obesity. Hyperforin also shows diverse pharmacological activities including anti-depression, anti-tumor, anti-dementia, anti-diabetes. Hyperforin modulates γδ T cells to secret IL-17α, improves Imiquimod (HY-B0180)-induced psoriasis-like mice model .

HY-N10426

(+)-Cembrene A	Glycosidase	Metabolic Disease
(+)-Cembrene A (Compound 5) is a α-glucosidase inhibitor with an IC₅₀ of 30.31 μM. (+)-Cembrene A is nontoxic towards human normal hepatocyte (LO2) cells .

HY-116330AR

Hyperforin dicyclohexylammonium salt (Standard)	TRP Channel Calcium Channel	Neurological Disease
Hyperforin (dicyclohexylammonium salt) (Standard) is the analytical standard of Hyperforin (dicyclohexylammonium salt). This product is intended for research and analytical applications. Hyperforin dicyclohexylammonium salt (Hyperforin DCHA) is a transient receptor canonical 6 (TRPC6) channels activator. Hyperforin dicyclohexylammonium salt modulates Ca2+ levels by activating Ca2+-conducting non-selective canonical TRPC6 channels. Hyperforin dicyclohexylammonium salt also shows diverse pharmacological activities including anti-depression, anti-tumor, anti-dementia, anti-diabetes. Hyperforin dicyclohexylammonium salt modulates γδ T cells to secret IL-17α, improves Imiquimod (HY-B0180)-induced psoriasis-like mice model .

HY-W010271

(2S,3R,4S)-4-Hydroxyisoleucine (2S,3R,4S)-4-Hydroxy-L-isoleucine	Insulin Receptor	Metabolic Disease
(2S,3R,4S)-4-Hydroxyisoleucine is an orally active compound. (2S,3R,4S)-4-Hydroxyisoleucine can be isolated from Trigonella foenum-graecum. (2S,3R,4S)-4-Hydroxyisoleucine has anti-diabetic and anti-diabetic nephropathy activity .

HY-108572

S26948	PPAR	Cardiovascular Disease Metabolic Disease
S26948 is a specific peroxisome proliferator-activated receptor γ (PPARγ) modulator (EC₅₀=8.83 nM) with potent antidiabetes and antiatherogenic effects. S26948 is a specific high-affinity agonist for PPARγ .

HY-B0089

Acarbose 3 Publications Verification BAY g 5421	Glycosidase	Metabolic Disease Cancer
Acarbose (BAY g 5421), antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC₅₀=11 nM). Acarbose can potentiate the hypoglycemic effects of sulfonylureas or insulin .

HY-B0089R

Acarbose (Standard)	Glycosidase	Metabolic Disease Cancer
Acarbose (Standard) is the analytical standard of Acarbose. This product is intended for research and analytical applications. Acarbose (BAY g 5421), antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC50=11 nM). Acarbose can potentiate the hypoglycemic effects of sulfonylureas or insulin .

HY-143269

HPA-IN-2	Amylases Glycosidase	Metabolic Disease
HPA-IN-2 (Compound 2a-1) is a potent and selective human pancreatic α-amylase (HPA) inhibitor with IC₅₀ values of 8.2 μM and 450.7 μM against HPA and α-glucosidase, respectively .

HY-143268

HPA-IN-1	Amylases Glycosidase	Metabolic Disease
HPA-IN-1 (Compound 1) is a potent and selective human pancreatic α-amylase (HPA) inhibitor with IC₅₀ values of 12.0 μM and 410.4 μM against HPA and α-glucosidase, respectively .

Cat. No.	Product Name

HY-L046

Anti-Cardiovascular Disease Compound Library	1,913 compounds
Cardiovascular diseases (CVDs) are a group of disorders of the heart and blood vessels which include coronary heart disease, cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, etc. CVDs are the number 1 cause of death globally. Smoking, unhealthy nutrition, aging population, lack of physical activity, arterial hypertension, or diabetes can promote cardiovascular disease like myocardial infarction or stroke. It is multifactorial and encompasses a multitude of mechanisms, such as eNOS uncoupling, reactive oxygen species formation, chronic inflammatory disorders and abnormal calcium homeostasis. Antioxidant, anti-inflammatory and anti-diabetes agents may reduce the cardiovascular disease risk. MCE supplies a unique collection of 1,913 compounds with confirmed anti-cardiovascular activity. These compounds mainly target metabolic enzyme, membrane transporter, ion channel, inflammation related signaling pathways. MCE Anti-Cardiovascular Disease Compound Library can be used for cardiovascular diseases related research and high throughput and high content screening for new drugs.

Anti-Cardiovascular Disease Compound Library

1,913 compounds

Cardiovascular diseases (CVDs) are a group of disorders of the heart and blood vessels which include coronary heart disease, cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, etc. CVDs are the number 1 cause of death globally. Smoking, unhealthy nutrition, aging population, lack of physical activity, arterial hypertension, or diabetes can promote cardiovascular disease like myocardial infarction or stroke. It is multifactorial and encompasses a multitude of mechanisms, such as eNOS uncoupling, reactive oxygen species formation, chronic inflammatory disorders and abnormal calcium homeostasis. Antioxidant, anti-inflammatory and anti-diabetes agents may reduce the cardiovascular disease risk.

MCE supplies a unique collection of 1,913 compounds with confirmed anti-cardiovascular activity. These compounds mainly target metabolic enzyme, membrane transporter, ion channel, inflammation related signaling pathways. MCE Anti-Cardiovascular Disease Compound Library can be used for cardiovascular diseases related research and high throughput and high content screening for new drugs.

HY-L040

Anti-diabetic Compound Library	901 compounds
Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage. The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes. MCE Anti-diabetic Compound Library owns a unique collection of 901 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.

Anti-diabetic Compound Library

901 compounds

Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage.

The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes.

MCE Anti-diabetic Compound Library owns a unique collection of 901 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.

Macelignan 3 Publications Verification (+)-Anwulignan; Anwuligan	Structural Classification Neurological Disease Classification of Application Fields Source classification Lignans Metabolic Disease Plants Monophenols Phenols Phenylpropanoids Schisandraceae Schisandra chinensis (Turcz.) Baill. Inflammation/Immunology Disease Research Fields	COX
Macelignan ((+)-Anwulignan; Anwuligan)?is an orally active lignan isolated from Myristica fragrans. Macelignan possesses many pharmacological activities, including anti-inflammatory, anti-cancer, anti-diabetes, and neuroprotective activities .

(2S,3R,4S)-4-Hydroxyisoleucine (2S,3R,4S)-4-Hydroxy-L-isoleucine	Structural Classification Classification of Application Fields Leguminosae Ketones, Aldehydes, Acids Source classification Metabolic Disease Plants Trigonella foenum-graecum Linn. Disease Research Fields	Insulin Receptor
(2S,3R,4S)-4-Hydroxyisoleucine is an orally active compound. (2S,3R,4S)-4-Hydroxyisoleucine can be isolated from Trigonella foenum-graecum. (2S,3R,4S)-4-Hydroxyisoleucine has anti-diabetic and anti-diabetic nephropathy activity .

Acarbose 3 Publications Verification BAY g 5421	Structural Classification Polysaccharides Microorganisms Classification of Application Fields Anti-aging Source classification Metabolic Disease Disease Research Fields Saccharides	Glycosidase
Acarbose (BAY g 5421), antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC₅₀=11 nM). Acarbose can potentiate the hypoglycemic effects of sulfonylureas or insulin .

Glyurallin A	Structural Classification Leguminosae Source classification Coumarins Phenylpropanoids Plants Glycyrrhiza uralensis Fisch.	Endogenous Metabolite Glycosidase
Glyurallin A (Compound 79) is isolated from the naturalGlycyrrhiza uralensis. Glyurallin A inhibitsα-Glucosidase(HY-P2802)(IC₅₀=0.3 μM). Glyurallin A can be used in the study of anti-diabetes .

Macelignan (Standard)	Structural Classification Monophenols Source classification Lignans Phenols Phenylpropanoids Plants Schisandraceae Schisandra chinensis (Turcz.) Baill.	COX
Macelignan (Standard) is the analytical standard of Macelignan. This product is intended for research and analytical applications. Macelignan ((+)-Anwulignan; Anwuligan) is an orally active lignan isolated from Myristica fragrans. Macelignan possesses many pharmacological activities, including anti-inflammatory, anti-cancer, anti-diabetes, and neuroprotective activities .

β-Amyrin palmitate	Triterpenes other families Classification of Application Fields Terpenoids Source classification Plants Disease Research Fields Endocrinology	HMG-CoA Reductase (HMGCR)
β-Amyrin palmitate shows HMG-CoA reductase inhibition . And β-Amyrin palmitate has anti-diabetes mellitus activity .

3-Acetyl-11-keto-ursolic acid	Structural Classification Ketones, Aldehydes, Acids Source classification Rosaceae Plants Eriobotrya japonica (Thunb.) Lindl.	Others
3-Acetyl-11-keto-ursolic acid (Compound 18) is a triterpenoid compound derived from Eriobotrya japonicaleaves. 3-Acetyl-11-keto-ursolic acid has 11B-hydroxysteroid dehydrogenase 1 (11b-HSD1) inhibitory activity. 3-Acetyl-11-keto-ursolic acid can be used for anti-diabetes research .

Hyperforin	Structural Classification Anti-inflammation/Immunoregulatory Antibiotics Guttiferae Source classification Hyperlcurn perforatum L. Disease Research Plants Anticancer	Calcium Channel TRP Channel
Hyperforin is a transient receptor canonical 6 (TRPC6) channels activator. Hyperforin modulates Ca ²⁺ levels by activating Ca ²⁺-conducting non-selective canonical TRPC6 channels and triggers adipose tissue thermogenesis via the Dlat-AMPK signaling axis to suppress obesity. Hyperforin also shows diverse pharmacological activities including anti-depression, anti-tumor, anti-dementia, anti-diabetes. Hyperforin modulates γδ T cells to secret IL-17α, improves Imiquimod (HY-B0180)-induced psoriasis-like mice model .

(+)-Cembrene A	Structural Classification Animals Terpenoids Source classification	Glycosidase
(+)-Cembrene A (Compound 5) is a α-glucosidase inhibitor with an IC₅₀ of 30.31 μM. (+)-Cembrene A is nontoxic towards human normal hepatocyte (LO2) cells .

Hyperforin dicyclohexylammonium salt (Standard)	Structural Classification Natural Products Guttiferae Source classification Hyperlcurn perforatum L. Plants	TRP Channel Calcium Channel
Hyperforin (dicyclohexylammonium salt) (Standard) is the analytical standard of Hyperforin (dicyclohexylammonium salt). This product is intended for research and analytical applications. Hyperforin dicyclohexylammonium salt (Hyperforin DCHA) is a transient receptor canonical 6 (TRPC6) channels activator. Hyperforin dicyclohexylammonium salt modulates Ca2+ levels by activating Ca2+-conducting non-selective canonical TRPC6 channels. Hyperforin dicyclohexylammonium salt also shows diverse pharmacological activities including anti-depression, anti-tumor, anti-dementia, anti-diabetes. Hyperforin dicyclohexylammonium salt modulates γδ T cells to secret IL-17α, improves Imiquimod (HY-B0180)-induced psoriasis-like mice model .

Acarbose (Standard)	Structural Classification Polysaccharides Microorganisms Source classification Saccharides	Glycosidase
Acarbose (Standard) is the analytical standard of Acarbose. This product is intended for research and analytical applications. Acarbose (BAY g 5421), antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC50=11 nM). Acarbose can potentiate the hypoglycemic effects of sulfonylureas or insulin .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks